Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors — a novel class of incretin analog currently characterized in published structure-activity research. This 30mg preparation is intended for longitudinal study designs and protocols requiring extended assay timelines.
Compound Profile
- Class: Triple incretin receptor agonist (GLP-1R / GIPR / GCGR)
- Form: Lyophilized peptide, sealed Type I borosilicate vial
- Receptor characterization: Documented via surface plasmon resonance + functional reporter assays in published literature
- Net content: 30 mg / vial
Quality & Documentation
- Purity: ≥99% verified by reverse-phase HPLC
- Identity: Confirmed by mass spectrometry
- Certificate of Analysis: Batch-specific, lot-traceable, available on request
- Manufacturing: cGMP-adjacent standards, validated cold-chain logistics
- Storage: Refrigerate at 36–46°F lyophilized; ~60 day stability reconstituted
Research Use
Designated for in-vitro and preclinical research applications only. Not intended for any form of human or veterinary use, dietary supplementation, or food-additive application.
